NCT00063999 · OUTCOME

Number of Participants Alive at Time of Last Follow-up.

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer · Source last updated 2021-10-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Patients were assessed during treatment. Following completion of treatment, follow up was assessed every 3 months for 2 years, then every 6 months for 3 years and annually after for a maximum of 10 years.

What was measured

The time alive in months from study entry to last contact or death.

Analysis population: Eligible and treated patients. Data are reported from the second interim analysis.

Groups in this outcome

Arm I (Doxorubicin, Cisplatin, Paclitaxel)

Patients receive doxorubicin IV over approximately 15-30 minutes on day 1, cisplatin IV over 60-90 minutes on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.

Arm II (Paclitaxel, Carboplatin)

Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm I (Doxorubicin, Cisplatin, Paclitaxel)	647
Arm II (Paclitaxel, Carboplatin)	665

Reported measurements

Source class 1

Alive

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Doxorubicin, Cisplatin, Paclitaxel)	376	Not reported	Not reported	Not reported	Not reported
Arm II (Paclitaxel, Carboplatin)	385	Not reported	Not reported	Not reported	Not reported

Dead

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Doxorubicin, Cisplatin, Paclitaxel)	271	Not reported	Not reported	Not reported	Not reported
Arm II (Paclitaxel, Carboplatin)	280	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
376
group Id
OG001
value
385
title
Alive
measurements
group Id
OG000
value
271
group Id
OG001
value
280
title
Dead

denoms

counts
group Id
OG000
value
647
group Id
OG001
value
665
units
Participants

description

The time alive in months from study entry to last contact or death.

groups

description
Patients receive doxorubicin IV over approximately 15-30 minutes on day 1, cisplatin IV over 60-90 minutes on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
id
OG000
title
Arm I (Doxorubicin, Cisplatin, Paclitaxel)
description
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
id
OG001
title
Arm II (Paclitaxel, Carboplatin)

param Type

COUNT_OF_PARTICIPANTS

population Description

Eligible and treated patients. Data are reported from the second interim analysis.

reporting Status

POSTED

time Frame

Patients were assessed during treatment. Following completion of treatment, follow up was assessed every 3 months for 2 years, then every 6 months for 3 years and annually after for a maximum of 10 years.

title

Number of Participants Alive at Time of Last Follow-up.

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice